The market has underappreciated Kiwi drug manufacturer AFT Pharmaceuticals’s core Australia business, says Forsyth Barr in a glowing note after expanding its coverage of the stock.
The NZX and ASX-listed company’s share price has been languishing this year, down 20% on a year ago but Forsyth
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
